Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

June 30, 2010

Study Completion Date

April 30, 2011

Conditions
Scleroderma
Interventions
DRUG

dasatinib

Tablets, Oral, 100 mg, once daily, 6 months

Trial Locations (13)

10021

Hospital For Special Surgery, New York

15261

University Of Pittsburgh, Pittsburgh

20007

Georgetown University Hospital, Washington D.C.

29425

Medical University Of South Carolina, Charleston

48106

University Of Michigan, Ann Arbor

49546

West Michigan Rheumatology, Grand Rapids

60611

Northwestern University Feinberg School Of Medicine, Chicago

85259

Mayo Clinic Arizona, Scottsdale

90095

Ucla Division Of Rheumatology, Los Angeles

06030

University Of Connecticut Health Center, Farmington

02118

Boston University School Of Medicine, Boston

08903

Umdnj Clinical Research Center, New Brunswick

02905

Rhode Island Hospital, Providence

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY